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Abstract 
Background: The Plasmodium vivax merozoite surface protein 1 paralog (PvMSP1P‑19) is a glycosylphosphati‑
dylinositol (GPI)‑anchored blood‑stage protein that is expressed on the merozoite surface. It is proposed as a 
blood‑stage vaccine candidate against P. vivax because of its ability to induce immune responses upon natural P. 
vivax exposure and in immunized animals. This study aimed to demonstrate the presence of inhibitory antibodies 
and memory B cell responses to the PvMSP1P‑19 antigen during acute P. vivax infection and after recovery from 
infection.
Methods: To evaluate the antibody responses to PvMSP1P‑19 during and after recovery from P. vivax infection, 
heparinized blood was collected from P. vivax‑infected patients and recovered subjects to detect the total IgG 
response. The seropositive samples were defined into high and low responders, according to their optical density 
(OD) values obtained from ELISA. High responders were the subjects who had OD values above the OD of antisera 
from non‑exposed controls plus 4× standard deviations, whereas low responders were the subjects who had OD 
values less than OD of antisera from non‑exposed controls plus 4× standard deviations. The plasma from high and 
low responders were taken for testing the inhibitory activity against PvMSP1P‑19‑erythrocyte binding by in vitro 
EBIA. The sustainability of PvMSP1P‑19‑specific memory B cell responses after recovery from infection was analysed 
by ELISPOT.
Results: The anti‑PvMSP1P‑19 antibody levels were significantly higher in acutely infected P. vivax patients com‑
pared to healthy controls (P <  0.0001). Monitoring of the anti‑PvMSP1P‑19 antibody titre showed that the antibody 
was maintained for up to 9 months after recovery. Almost all high‑responder groups strongly inhibited PvMSP1P‑19 
binding to erythrocytes, whereas no inhibition was shown in most low‑responder samples. Interestingly, the inhibi‑
tory activity of the antibodies in some individuals from high‑responder samples were stable for at least 12 months. 
The longevity of the antibody response was associated with the presence of PvMSP1P‑19‑specific memory B cells at 
9 months after recovery from infection.
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Background
Plasmodium vivax, the most frequent cause of recurring 
malaria, is widely distributed throughout Latin Amer-
ica, some parts of Africa and Southeast Asian countries 
[1–3]. An estimated 2.85 billion people worldwide are at 
risk of vivax malaria and approximately 65% of cases are 
from Asian and South American regions [4]. The major 
features of P. vivax that distinguish it from other Plas-
modium species are its high transmission potential from 
early and continuous gametocyte production, its hiber-
nating behaviour in the liver in the form of hypnozoites, 
its shorter life cycle and its high infectivity in vectors, 
which are the primary obstacles to controlling this type of 
malaria [5]. In this regard, the development of a vaccine to 
attack vivax malaria is urgently needed to reduce morbid-
ity and mortality related to malaria. However, due to tech-
nical limitations such as lack of continuous culture, the 
development of effective vivax vaccine has been delayed, 
and the eradication of vivax malaria is still challenging.
Among three types of vaccine candidates-pre-eryth-
rocytic, erythrocytic and transmission blocking-the 
erythrocytic approach is targeted primarily toward mini-
mizing the morbidity, mortality and parasitaemia levels. 
Blood stage antigens such as apical membrane protein 
1 (AMA-1), merozoite surface protein 1 (MSP-1) and 
Duffy-binding protein (DBP) are major targets for blood-
stage vaccine development because they are responsible 
for the clinical manifestation and merozoite invasion of 
red blood cells in humans [6]. It is possible to acquire 
immunity against blood stage antigens in natural expo-
sure-derived P. vivax infections. Similarly, protection 
against P. vivax infection could be induced by numerous 
immunization strategies [7]. However, the rapid mutation 
of the blood-stage antigens is the primary challenging 
problem in its vaccine development. In fact, an effective 
vaccine must be able to induce both humoral and cellular 
immune responses without having any genetic restriction 
while stimulating memory cells. Therefore, the discovery 
of potential vaccine antigens and a better understanding 
of the underlying immune mechanisms against parasites 
in natural infections will guide us to progress further in 
developing this vaccine.
Recently, a new vaccine candidate has emerged for 
blood stage vivax malaria infections called Plasmodium 
vivax merozoite surface protein 1 paralog (PvMSP1P-19), 
which is located at the upstream locus of the MSP1 gene. 
It was identified as a paralog of PvMSP1, and it showed 
similarities in the size, molecular mass, number and loca-
tion of cystine residue, whereas it was not expressed as a 
highly polymorphic protein as was PvMSP1 [8, 9]. Inter-
estingly, PvMSP1P-19 was found to contain double epi-
dermal growth factor (EGF)-like domains, which assist in 
merozoite invasions of erythrocytes. As a consequence, 
the rosette forms of PvMSP1P-19-transfected COS7 cells 
and human erythrocyte binding observed during in vitro 
study was stronger than those seen in PvMSP1-infected 
cells. This result assures us that the function of PvM-
SP1P-19 is to play a role as a parasite ligand for invasion. 
Additionally, another advantage of PvMSP1P-19 is that 
both the N- and C-terminal regions have high potential 
for inducing host immune responses, and the resulting 
antibodies inhibit PvMSP1P-19-erythrocyte binding [10]. 
Another study also reported that PvMSP1P-19 strongly 
induces the activation of IFN-γ-producing effector cells 
following natural P. vivax exposure, suggesting that it 
has the potential to activate the recall response of Th1 
effector memory cells [11]. These data all suggested that 
PvMSP1P-19 is reliable at inducing the inhibitory anti-
body and at promoting good immunogenicity. However, 
to be sure that PvMSP1P-19 antigen has the ability as a 
vaccine candidate, further studies are needed. Hence, in 
this study, the longevity of a naturally acquired antibody 
against the PvMSP1P-19 antigen was evaluated because 
it would be an important factor for determining the qual-
ifications of the vaccine. Another objective of this study 
is to observe the specific memory B cell (MBC) response 
to PvMSP1P-19 in P. vivax-infected patients to acquire a 
better understanding of the underlying immune mecha-
nisms and to develop an effective malaria vaccine in the 
future.
Methods
Study area and sample collection
To observe the antigenicity of PvMSP1P-19 antigen dur-
ing acute and convalescence phase and the maintenance 
of anti-PvMSP1P-19 responses after recovery from P. 
vivax infection, both cross-sectional survey and lon-
gitudinal cohort study were performed between May 
Conclusions: The PvMSP1P‑19 antigen has immunogenicity during the induction of the antibody response, in which 
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2014–October 2016 in a low-malaria-transmission area, 
Rap Ro malaria clinic, Chumphon Province, which is 
located in the southern part of Thailand where both P. 
vivax and Plasmodium falciparum commonly occur.
The antigenicity of PvMSP1P-19 in induction of antibody 
response in natural infection at acute malaria infection and 
after recovery from infection was explored. Ten milliliters 
of heparinized peripheral blood samples were collected 
from P. vivax acutely infected patients (n = 40) and from 
P. vivax subjects who had recovered from the infection 
at 3 months (n = 27), 9 months (n = 15) and 12 months 
(n = 14). In addition, the malaria endemic villagers (n = 15) 
who lived in the same village as acutely infected patients for 
more than 5 years showed negative parasitaemia in blood 
smears at the time of collection as well as have no history of 
malaria infection was recruited in this survey. The ages of 
subjects ranged from 18 to 63 years old.
The maintenance of anti-PvMSP1P-19 response after 
recovery from infection was demonstrated from a lon-
gitudinal analysis. Among 40 P. vivax infected patients, 
16 infected individuals were followed antibody response 
at acute phase and after they recovered from infection 
for 3  months. Moreover, five infected individuals were 
followed anti-PvMSP1P-19 responses after 3, 9 and 
12  months recovery from infection. Giemsa staining by 
thick and thin peripheral blood films was used for diag-
nosis, and nested PCR was performed to confirm the P. 
vivax infection. Individual samples were taken for plasma 
preparation and used for enzyme-linked immunosorbent 
assays (ELISA) and erythrocyte binding inhibition assays 
(EBIA).
The presence of memory B cell responses to the PvM-
SP1P-19 antigen after recovery from P. vivax infection 
was demonstrated by collecting peripheral blood mono-
nuclear cell (PBMC) samples (n =  11) from individuals 
during acute phase and after 9  months recovery from 
infection with P. vivax between June 2016 and March 
2017. Blood samples from healthy persons (n = 22) from 
the Faculty of Medical Technology, Mahidol University 
who had never been exposed to malaria in their lives were 
collected as healthy controls for this study. The study was 
approved by the Committee on Human Rights Related 
to Human Experimentation, Mahidol University, and the 
Ministry of Health, Thailand (MUIR 2012/079.2408).
Recombinant PvMSP1P‑19 protein expression
The recombinant protein PvMSP1P-19 was expressed 
and purified as previously described [10]. Briefly, the 
gene fragment encoding PvMSP1P-19, which was 
obtained from the genomic DNA of the P. vivax SalI 
strain sequence, was amplified by PCR and cloned into 
the XhoI and NotI sites of the pEU-E01-His-TEV-MCS 
vector (Cell Free Sciences, Matsuyama, Japan). An ABI 
PRISM 310 Genetic Analyzer and a BigDye Termina-
tor v1.1 Cycle Sequencing kit (Applied Biosystems, Fos-
ter City, CA, USA) were used to confirm the inserted 
nucleotide sequence. For the in  vitro transcription and 
subsequent translation, highly purified plasmid DNA 
was prepared by using a Maxi Plus™ Ultrapure plasmid 
extraction system (Viogene, Taipei, Taiwan) in accord-
ance with the manufacturer’s instructions. For recombi-
nant protein expression, the purified DNA was eluted in 
0.1× TE buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA) 
and used in a wheat germ cell-free (WGCF) system (Cell-
Free Sciences) as described previously [12, 13]. After that, 
the newly synthesized recombinant PvMSP1P-19-19 pro-
tein was purified using a nickel-nitrilotriacetic acid (Ni–
NTA) column (Qiagen, Hilden, Germany).
Detection of total IgG responses to PvMSP1P‑19
The levels of the antibody response against PvMSP1P-19 
in individuals with P. vivax exposure were measured by 
indirect ELISA. In brief, 5 μg/mL of recombinant PvM-
SP1P-19 protein was used to coat 96-well ELISA plates 
overnight at 4  °C. Then, 100  μL of 5% skim milk was 
added to each well and incubated for 2 h. Next, the plates 
were washed twice with washing buffer (0.05% Tween-
20 in 1× PBS), and 50  μL of 1:200 diluted plasma was 
added to specific wells of the coated plate and incubated 
for 1 h. After that, the wells were washed again, followed 
by the addition of 50  μL of affinity-purified peroxidase-
labelled goat anti-human IgG (H+L) antibody, which 
was diluted 1:1000 with blocking buffer. After 90 min of 
incubation at room temperature, another washing step 
was needed. After that, 50 μL of 2,2′-azino-bis(3-ethylb-
enzothiazoline-6-sulphonic acid) (ABTS) substrate solu-
tion was added. The ELISA plates were incubated for 
45 min in the dark at room temperature. Finally, the opti-
cal density (OD) of each sample well was measured with 
an ELISA plate reader (SYNERGY™ HTX multi-mode 
reader, BioTek) at 405 nm  (OD405). All the samples were 
analysed in duplicate and mean values were used in the 
analyses. The cut-off value was obtained from the mean 
plus two standard deviations (SDs) of the OD of all of the 
non-exposed Thai plasma samples. Based on ELISA data, 
the seropositive samples were classified into the follow-
ing two groups: high responders (OD ≥ mean + 4SD of 
non-exposed Thai control plasma; 0.039–0.137) and low 
responders (OD < mean + 4SD of non-exposed Thai con-
trol plasma; 0.022–0.037).
Erythrocyte binding inhibition assay of anti‑PvMSP1P‑19 
antibody
In this study, human embryonic kidney 293 cells carry-
ing the SV40 large T antigen (HEK293-T) were used in 
an EBIA specific to PvMSP1P-19. The cells were grown in 
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Dulbecco’s modified Eagle medium (DMEM) (Gibco, Inv-
itrogen, Paisley, UK) with 10% fetal bovine serum (FBS) 
(Gibco) at 37 °C with 5% atmospheric  CO2. The cells were 
passaged when they reached 90–100% confluence. A 
2 × 104 concentration of cells was transferred into each 
well of a 24-well culture plate (Corning Inc., Corning, 
NY, USA). Next, the cells were transfected with 50 μL of 
DNA-liposome complex, and 100  ng of diluted plasmid 
pEGFP-MSP1P was mixed with 2%  Lipofectamine®2000 
(Invitrogen, Carlsbad, CA, USA) and incubated at 37 °C 
in a 5%  CO2 chamber for 42–44 h. The transfection effi-
ciencies were determined by observing the expression of 
green fluorescence protein (GFP) under an inverted fluo-
rescence microscopy. The HEK293-T cells with transfec-
tion efficiencies of >80% were used for the EBIA.
To test the inhibition of the antibodies, 250 μL of 1:10 
diluted plasma was added to transfected HEK293-T cells 
containing culture plate wells and incubated for 1  h at 
37 °C. Then, 50 μL of 10% Duffy-positive human packed 
red blood cells was added to each well. The plates were 
incubated for 2  h, followed by the removal of the non-
adherent erythrocytes by washing them with washing 
buffer (1× PBS with  Mg2+ and  Ca2+). Rosette-forming 
transfected HEK293-T cells in which adherent erythro-
cytes covered >50% of the HEK293-T cell surface were 
quantified under the 20× magnified objective lens of an 
inverted microscope (Olympus, CKX41, UK) for 30 fields 
per well. The plasma samples obtained from non-malaria 
naive individuals were considered negative controls, 
and mouse monoclonal antibodies against PvMSP1P-19 
were used as the positive control. The percent binding-
inhibition of each subjects was determined by assessing 
the number of rosettes in wells of transfected HEK293-T 
cells in the presence of P. vivax human plasma relative to 
rosettes in wells of transfected cells in presence of non-
exposed Thai control plasma. Individual samples were 
dispensed into duplicate wells, and the whole experiment 
was repeated three times.
Preparation of peripheral blood mononuclear cells
To demonstrate the presence of MBCs specific to the 
PvMSP1P-19 antigen, PBMC samples from individuals 
who had recovered from P. vivax infection for 9 months 
(n = 11) were taken for MBC phenotyping and ELISPOT 
assays. The PBMCs were prepared from heparinized 
blood, for which the blood was diluted with incomplete 
RPMI 1640 medium (Gibco, Invitrogen, Paisley, UK) at 
a 1:1 proportion. To separate the PBMCs, diluted blood 
was overlaid on Ficoll-Hypaque (Stemcell Technologies, 
Vancouver, Canada). The overlaid blood sample was 
centrifuged for 30 min at 2000 rpm and 18 °C. The lym-
phocytes were harvested and washed twice at 1500 rpm 
for 10  min at 4  °C, then resuspended in R10 medium 
(incomplete RPMI media supplement with 10% FBS and 
100 units/mL penicillin, with 100 μg/mL streptomycin). 
Later, the cell counting process and cell viability evalua-
tion were performed by Trypan blue exclusion test.
Phenotyping memory B cells
To phenotype the MBCs, approximately 1 × 106 PBMCs 
were stained with a panel of fluorochrome-conjugated 
monoclonal antibodies that consisted of anti-human 
CD19-FITC  (Biolegend®, San Diego, CA, USA), anti-
human CD10-PE Cy7  (Biolegend®) and anti-human 
CD27-PE  (Biolegend®) and incubated for 15 min at 4 °C. 
The cells were washed with 500  μL of FACS buffer at 
1500  rpm for 5 min at 4  °C. Then, the cells were resus-
pended in 250 μL of FACS buffer. Finally, the stained cells 
were phenotyped by flow cytometry (BD FACSCanto™; 
Becton–Dickinson, Oxford, UK) and the resulting data 
were analysed by FlowJo (v. 7.0; Tree Star Inc., San Car-
los, CA, USA).
PBMCs from stimulation for the ELISPOT assay
Before the ELISPOT assay was performed, PBMCs 
were first stimulated with polyclonal activator R848 and 
recombinant human IL-2 (Mabtech AB, Stockholm Uni-
versity, Sweden). During the cell stimulation process, 
1 × 106 cells per mL were seeded into the 24-well culture 
plate (Corning Inc.). In parallel to the stimulated sam-
ples, non-stimulated samples were also employed. All the 
samples were incubated at 37 °C in a humidified 5%  CO2 
incubator for 72 h.
ELISPOT assay
MultiScreen Filter PVDF Immobilon plates (Merck Mil-
lipore, Darmstadt, Germany) were treated with 35% 
ethanol for 1 min prior to being washed five times with 
sterile water. The wells were then coated overnight at 
4  °C with 15  µg/mL of monoclonal antibodies of anti-
human IgG (clones MT91/145; Mabtech), 10  µg/mL of 
recombinant PvMSP1P-19 or PvMSP1 antigen, or 5 µg/
mL of tetanus toxoid (TT) antigen (Merck Millipore, 
Darmstadt, Germany) diluted in sterile PBS. The plates 
were washed with 200  µL of sterile PBS five times and 
blocked with 200 µL of R10 for at least 30 min at 37  °C 
in 5%  CO2. Both the stimulated and non-stimulated 
cells were harvested from the culture plates, counted 
and seeded in duplicate to yield 5 ×  104  cells per anti-
human IgG-coated well and 1  ×  106  cells per specific 
antigen-coated well. After 24  h of incubation at 37  °C 
and 5%  CO2, the plates were then washed with PBS five 
times. Then, 1 µg/mL of detection monoclonal antibod-
ies MT78/145 (Mabtech) diluted in PBS-0.5% FBS were 
added and incubated for 2 h at room temperature. After 
five washes with PBS, the immobilized IgG was labelled 
Page 5 of 12Min et al. Malar J  (2017) 16:354 
using streptavidin–horseradish peroxidase (HRP)-conju-
gated polyclonal goat anti-human IgG (Mabtech) diluted 
to 1:1000 in PBS-0.5% FBS; Mabtech) and incubated for 
1  h at room temperature. Following a thorough wash-
ing with PBS, tetramethylbenzidine (TMB) substrate 
(Mabtech) was added. The filtered plates were rinsed 
with deionized water after distinct spots emerged. Anti-
gen-specific MBCs were expressed as spot-forming cells 
(SFC) in the wells. The plates were then left to dry and 
stored to protect them from light until they could be 
analysed with a Bioreader 5000 Pro-F gamma ELISPOT 
Reader (BioSys GmbH, Karben, Germany). PBMCs from 
P. vivax subjects that were cultured without stimulation 
and then incubated overnight with PvMSP1P-19 anti-
gens were used as negative controls. The positive ELIS-
POT response was defined when spots were detected in 
duplicate wells and the total spots in the specific antigen-
coated well reached at least twice the number of spots 
detected in the negative controls.
Statistical analysis
The data were analysed using GraphPad Prism software 
(Systat Software, San Jose, CA, USA) and Microsoft Excel 
2007. The nonparametric Mann–Whitney U test was 
used to determine the significant difference of the anti-
body titre level against PvMSP1P-19 antigen in P. vivax 
malaria-exposed subjects, endemic villagers and healthy 
controls. An unpaired t-test was used to measure the 
significant difference between the acute phase and after 
3  months recovery from infection groups from same 
individual. The  CD19+ total B cells and MBC frequencies 
between different time points in the same individual were 
compared by paired t-test. MBCs specific to PvMSP1P-19 
antigens and TT antigens between stimulated PBMCs 
and the non-stimulated negative control were compared 
by using a Wilcoxon matched-pairs signed rank test. In 
all the analyses, P values of less than 0.05 (P <  0.05) were 
deemed to indicate statistical significance.
Results
Naturally acquired IgG responses to PvMSP1P‑19
To evaluate the serological response against the PvM-
SP1P-19 antigen in natural P. vivax exposure, the anti-
body levels in plasma from acute P. vivax infection, 
endemic villagers and healthy controls were determined. 
The result showed that there was a significantly higher 
antibody level in acutely P. vivax-infected subjects in rela-
tion to the healthy controls (average OD values: P. vivax 
patients = 0.039, healthy controls = 0.010, P < 0.0001) as 
well as significant differences in endemic villagers rela-
tive to the healthy controls (endemic villagers  =  0.023, 
healthy controls  =  0.010, P  =  0.0037). Moreover, the 
antibody titre in acute patients was higher than that of 
endemic villagers (P. vivax patients = 0.039, endemic vil-
lagers = 0.023, P = 0.0089) (Fig. 1). According to the anti-
body titres in the individuals, 29 patients (72.5%) were 
seropositive for PvMSP1P-19. The seropositive individu-
als were classified as high responder (n = 16, OD > 0.039) 
and low responder (n = 13, OD < 0.037) groups (Fig. 1). 
There were six individuals (40%) from endemic villagers 
who produced antibodies to PvMSP1P-19 antigen. These 
data suggest that the PvMSP1P-19 antigen has immuno-
genicity and induces antibody production during natural 
infection.
Longevity of anti‑PvMSP1P‑19 antibody responses
A follow up study of anti-PvMSP1P-19 responses in 
individual patients during acute phase and the recovery 
period at 3, 9 and 12 months showed that 72.5, 70.4, 67.9 
and 21.4% were seropositive for PvMSP1P-19, respec-
tively (Table  1). There were no significant differences in 
the levels of antibodies between subjects who had been 
recovered from infection at 3  months and 9  months 
compared to the acute infected patients (P = 0.6681 and 
P = 0.7265, respectively) (Fig. 2a). However, at 12 months 
after recovery from infection, the antibody levels were 
significantly reduced compared to the acutely infected 
patients (P = 0.0067) (Fig. 2a).
To explore the maintenance of antibody responses 
to PvMSP1P-19 during convalescence, the persistence 
of anti-PvMSP1P-19 antibody titre in individuals was 
observed after recovered from infection at 3  months. 
81% of the patients had persistent antibody responses at 
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Fig. 1 Humoral immune response to PvMSP1P‑19. The antibody 
levels were detected in human plasma from acutely P. vivax‑infected 
patients (n = 40), villagers in endemic areas (n = 15) and naïve 
controls (n = 22). Each symbol represents an individual sample. The 
dashed line indicates the cut‑off value [mean ± 2 standard deviations 
(SD) of the optical density (OD) value of malaria‑naïve individuals]. A 
nonparametric Mann–Whitney U test was used to assess the signifi‑
cant difference in the antibody titre levels against the PvMSP1P‑19 
antigen. The level of significance was set at a P value <0.05
Page 6 of 12Min et al. Malar J  (2017) 16:354 
3 months after recovery. There was no significant differ-
ence in the antibody titres between samples from acute 
patients and those at 3 months after recovery from infec-
tion (P = 0.0966, Fig. 2b). Thus, for the further analysis of 
the antibody response persistence, 5 individual patients 
(HR1, HR2, HR3, LR1 and LR2) were followed for their 
antibody titres up to 12 months after recovery from the 
infection. The results showed that the anti-PvMSP1P-19 
responses in HR1 and HR3 were maintained at a sero-
positive level for up to 12 months after recovery from the 
infection, whereas the antibody titre in HR2 was seron-
egative at 9 months after treatment. In addition, the LR1 
and LR2 were seronegative at 9  months after recovery 
from infection (Fig. 2c). These analyses suggest that anti-
body response to PvMSP1P-19 are stably maintained 
after recovery from infection.
The inhibitory activity of anti‑PvMSP1P‑19 antibody 
against erythrocyte binding
To evaluate the inhibitory efficiency of the anti-PvM-
SP1P-19 antibodies, plasma samples from high responders 
and low responders among the acutely P. vivax-infected 
subjects (n = 29) were taken for in vitro EBIA. Among the 
16 high responders, 12 individuals produced high levels 
of inhibitory antibodies against PvMSP1P-19 binding to 
erythrocytes, at >80% inhibition activity, whereas the anti-
bodies from 4 patient samples (HR10, HR11, HR13 and 
HR16) exhibited low inhibitory activity (Fig.  3a). In low 
responders (n = 13), or almost all the patients, 9 samples 
had a low ability to inhibit PvMSP1P-19-erythrocyte bind-
ing, at <80% inhibition activity. Only 4 patients strongly 
blocked human erythrocyte binding (LR5  =  82.1%, 
LR6 = 90.4%, LR7 = 93.6% and LR11 = 84.2%) (Fig. 3b).
In addition, the longevity of anti-PvMSP1P-19 anti-
bodies against erythrocyte binding after anti-malarial 
treatment was observed from the HR and LR groups 
(n  =  5) by following up with their acute and recov-
ery phases after infection. The activity of inhibitory 
antibodies against PvMSP1P-19-erythrocyte bind-
ing in HR1 and HR3 was maintained by showing the 
inhibition percentages >80% at the acute and recov-
ery phases. By contrast, the function of inhibitory 
antibodies in HR2 was not stable, and it showed a 
significant reduction at 9 and 12  months after recov-
ery from infection (acute phase  =  91.0%, 9  months 
recovery phase  =  68.7% and 12  months recovery 
phase  =  67.2%). In low responders, the antibodies in 
LR1 and LR2 weakly inhibited PvMSP1P-19-erythro-
cyte binding at the acute phase, and this process was 
continuously reduced during the convalescence period 
(Fig. 3c).
Memory B cell surface analysis during acute phase 
and after recovery from infection
As anti-PvMSP1P-19 antibodies were produced in most 
of the patients at acute infection, and maintained in some 
individuals at their recovery phases, the maintenance of 
total B cells and MBCs were considered for analysis. Here, 
the frequency of  CD19+ B cells and  CD10−CD19+CD27+ 
MBCs were demonstrated in P. vivax-infected individuals 
by flow cytometric analysis at the acute phase in compari-
son with their recovery periods at 3 and 9 months (Fig. 4a). 
The comparison of  CD19+ B cells in acutely infected P. 
vivax patients from the same population during the follow-
up to their recovery showed a greatly expansion of  CD19+ 
B cells at 3 months recovery from infection (P = 0.0005, 
Table 1 A mass blood survey of the antibody responses to PvMSP1P-19 during acute phase and after recovery from  P. 
vivax infection
a Time point the times at which the P. vivax-infected blood samples were collected
b Total (n) the total numbers of samples collected at each time point
c Number of positive (%) the number of seropositive individuals who had OD values greater than the cut-off value (mean ± 2 SD of the OD value of malaria-naïve 
individuals)
d Min the lowest antibody level at each time point
e Max the highest antibody level at each time point
f Median the median OD value of antibody levels at each time point
g SD the standard deviation of the antibody levels at each time point
h P value P value of the difference between the mean antibody levels of P. vivax-infected subjects and malaria-naïve subjects that were compared using the Mann–
Whitney U test
Time  pointa Total (n)b No. positive (%)c OD values Significance
Mind Maxe Medianf SDg P  valueh
Acute phase 40 29 (72.5) 0.010 0.176 0.032 0.029 <0.0001 Acute vs healthy controls
3 months recovery 27 19 (70.4) 0.001 0.112 0.033 0.025 0.6681 Acute vs 3 months recovery
9 months recovery 28 19 (67.9) 0.001 0.093 0.032 0.023 0.7265 Acute vs 9 months recovery
12 months recovery 14 3 (21.4) 0.008 0.109 0.018 0.026 0.0067 Acute vs 12 months recovery
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Fig. 4b). Interestingly, the analysis of  CD10−CD19+CD27+ 
MBC numbers in acute infection compared to the con-
valescence phase showed no significant difference in the 
MBC numbers (3  months recovery phase; P  =  0.5985, 
9 months recovery phase; P = 0.2412) (Fig. 4c).
Memory B cell response specific to the PvMSP1P‑19 
antigen after recovery from infection
Because the persistence of  CD10−CD19+CD27+ MBCs 
were detected in individuals at 9 months recovery from 
infection, the presence of PvMSP1P-19-specific MBCs 
was demonstrated in the study. PBMC samples from 11 
individuals who had recovered from P. vivax infection 
for 9  months were cultured for ELISPOT assays. The 
analysis of PvMSP1P-19-specific MBCs showed that 
all the patients (11/11) were positive. The median fre-
quency of PvMSP1P-19-specific MBCs and TT-specific 
MBCs among responders were 25 and 16 spots per mil-
lion PBMCs, respectively (Fig. 5a). PvMSP1P-19-specific 
MBCs were detected in all the samples (11/11) from 
patients at 9  months recovery from infection, whereas 
8 samples (88.9%) were positive for TT-specific MBCs 
(Fig.  5a). Approximately 81.8% (9/11) of the individu-
als who were positive for PvMSP1P-19-specific MBCs 
were seropositive in relation to the antibody titre, 
whereas 2 samples from seronegative ELISAs were posi-
tively detected in PvMSP1P-19-specific MBC responses 
(Fig.  5b). All the samples showed a correlation between 
the anti-TT antibody responses and TT-specific MBCs. 
Moreover, PvMSP1-specific MBCs were also positive at 
9 months recovery from infection, at 4–25 spots per mil-
lion PBMCs. As expected, PvMSP1P-19-specific MBCs 
were not detected in healthy controls that had no history 
of exposure to malaria.
Discussion
The aim of the blood stage malaria vaccine is to limit 
parasite growth during the stage that occurs within red 
blood cells and to prevent the clinical symptoms and 
pathology of malaria. However, most of the vaccines that 
are currently under development are in a pre-clinical 
study. The high polymorphisms of many leading candi-
date blood stage antigens are a major challenge for devel-
oping an effective vaccine against diverse strain of the 
parasites [14, 15]. The PvMSP1 paralog is GPI-anchored 
protein that is expressed on the merozoite surface, which 
is involved erythrocyte receptor binding [8]. In com-
parison with PvMSPs, it has a limited number of poly-
morphisms and is highly conserved [8]. For the ability 
in immune stimulation, cellular and antibody mediated 
immune responses against PvMSP1P-19 was developed 
in P. vivax-exposed patients [10, 11]. The antibody from 
antisera and P. vivax human plasma strongly blocked the 
binding to human erythrocytes, indicating PvMSP1P-19 
antigen contain epitope recognized by inhibitory anti-
bodies. To consider PvMSP1P-19 as a blood-stage vac-
cine candidate, better understanding long-lived immune 
response against this protein could be useful for vivax 
malaria protection.
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Fig. 2 Longevity of the antibody response to the PvMSP1P‑19 anti‑
gen after recovery from infection. a A survey of antibody responses 
during the acute phase (n = 40) and after anti‑malarial treatment at 
3 months (n = 27), 9 months (n = 28) and 12 months (n = 14). The 
bars represent the mean values. Mann–Whitney U test was used for 
statistical analysis and P value calculation. The level of significance 
was set at a P value <0.05. b The stability of the anti‑PvMSP1P‑19 
antibody responses in the same individual (n = 16) during acute 
phase and at 3‑month recovery phase. c A longitudinal cohort 
analysis of anti‑PvMSP1P‑19 response persistence in seropositive indi‑
viduals (n = 5, HR1 = Pv01, HR2 = Pv02, HR3 = Pv03 , LR1 = Pv04, 
LR2 = Pv05) at their acute phases and by following‑up their recovery 
phases at 3, 9 and 12 months. The dashed line indicates the cut‑off 
value (means ± 2SD of the OD value of malaria‑naïve individuals)
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In this study, the follow up seroprevalence of anti-
PvMSP1P responses demonstrated a high prevalence of 
antibody responses, approximately 72.5, 70.4 and 67.9% 
at acute phase, 3 months recovery and 9 months recovery 
phases, respectively. Furthermore, a longitudinal cohort 
study of anti-PvMSP1P-19 response in 16 individuals at 
acutely infected phase and after 3-month recovery from 
infection showed the stability of antibody titres in the 
absence of reinfection. Interestingly, some patients main-
tained their antibody response up to 12-month recovery 
from infection. These data were in line with other stud-
ies which showed the maintenance of antibody response 
to  PfMSP119 and PfMSP-142 and PvRAMA after recov-
ery from infection in individuals who were living in low-
transmission areas [16–19]. However, in endemic areas 
with high malaria infection rate had an impact on the 
efficiency of the antibody response development. Anti-
PfMSP1 response was not sustained during the long dry 
season in Sudan following anti-malarial drug treatment 
and parasite clearance. Here, the data support the per-
sistence of antibody response to malaria antigen after 
recovery from infection in low-transmission areas.
Antibody to PvMSP1P-19 had inhibitory activity 
against erythrocyte binding, approximately 75% of high 
responders and 30.76% of low responders strongly inhib-
ited PvMSP1P-19 binding to erythrocytes. Importantly, 
the inhibitory activity was maintained after 12  months 
recovery from infection in some individuals, suggesting 
P. vivax patients could produce antibodies against PvM-
SP1P-19 binding to erythrocytes during acute phase, and 
they can maintain this antibody after recovering from 
the infection. With regard to the association between 
the in  vitro inhibition assay of antibodies and the clini-
cal protection in malaria infection, the cohort study 
had been demonstrated in PvDBP vaccine candidates. 
The maintenance of naturally acquired inhibitory anti-
body responses decreased the risk of P. vivax malaria in 
rural Amazonians [20] and conferred protection from 
blood stage P. vivax infection [21]. Here, the functional 
assay of anti-PvMSP1P-19 inhibitory antibody was well 
demonstrated, further study is required to demonstrate 
the association between stability of inhibitory antibody 
responses and its protection from P. vivax malaria.
The association between long-lived anti-PvMSP1P-19 
responses and the persistence of peripheral  CD19+ B 
cells after recovery from infection was observed. How-
ever, during acute phase, the total  CD19+ B cells were 
reduced compared to non-malaria naive and during 
convalescence. This data was consistent with previous 
findings of P. falciparum infection study [22, 23]. The 
reduction of total  CD19+ B cells could be explained by 
the temporary reallocation of lymphocytes from the 
peripheral circulation to the tissues or lymphoid organs 
following infection [24], or it might occur through the 
evasive mechanism of Plasmodium upon the disruption 
of B cell lymphopoiesis and the induction of B cell apop-
tosis as reported in a mouse model [25, 26]. In addition, 
the expansion of  CD19+ B cell frequency at 3-month 
recovery phase may explain the homeostatic regulation 
of immune system after parasite clearance as there was 
no significant difference of  CD19+ B cells population 
between 3-month recovery from infection and malaria 
naive individuals, and the expansion of  CD19+ B cell was 
not correlated with antibody levels in this recovery phase.
After recovery from P. vivax infection, the mainte-
nance of  CD10−CD19+CD27+ MBCs was associated 
with positive PvMSP1P-19-specific MBC responses and 
circulating antibody titre. However, the positive corre-
lation between peripheral  CD10−CD19+CD27+ MBCs 
and the number of positive spots for PvMSP1P-specific 
MBC response was not observed. These data suggest that 
the natural infection could induce PvMSP1P-19-specific 
MBC development, and those MBCs are able to differ-
entiate among antibody-secreting cells to maintain the 
long-term antibody responses to this antigens in the 
absence of reinfection as parasitaemia at 3 and 9 months 
recovery from infection showed negative by nested PCR. 
However, the persistence of specific MBCs to the malaria 
antigens is still unclear. In low-transmission areas, MBCs 
specific to P. falciparum MSP-1 antigen and the P. vivax 
antigens, AMA1 and MSP1-19 was retained after recov-
ery from infection [16, 17, 27]. By contrast, some data 
from high-malaria-transmission regions showed the 
expansion of P. falciparum AMA1- and MSP1-specific 
MBCs in acute infection, and then memory cells were 
contracted to a point slightly higher than pre-infection 
levels after 6 months of decreased P. falciparum exposure 
(See figure on previous page.) 
Fig. 3 Inhibitory activity of antibodies against PvMSP1P‑19 binding to human erythrocytes. Seropositive plasma samples from acutely P. vivax‑
infected a high responders (n = 16) and b low responders (n = 13) were performed to evaluate the inhibitory activity of antibodies against PvM‑
SP1P‑19‑erythrocyte binding. c The activity of the anti‑PvMSP1P‑19 inhibitory antibody against human erythrocyte binding in individuals (n = 5) 
in their acute phases and their recovery phases at 9 and 12 months after P. vivax infeciton. The transfected HEK293‑T cells expressing PvMSP1P‑19 
were incubated with plasma and with human erythrocytes. The numbers of rosettes were compared between wells of transfected cells that were 
incubated with plasma of vivax malaria patients relative to the negative control well. The charts show the mean inhibition of each P. vivax subject. 
Error bars represent ± standard deviation
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[28]. Here, the persistence of PvMSP1P-19-specific 
MBC response after recovery from infection supports 
the hypothesis that MBC responses are more stable in 
low-malaria-transmission areas. In addition, the positive 
PvMSP1P-19-specific MBC response but negative for 
antibody titre in 2 adult children suggests that immunity 
to PvMSP1P-19 can develop persisting MBC responses 
in some individuals since the initial infection of malaria.
Conclusions
These results demonstrated that the PvMSP1P antigen 
is immunogenic to induce humoral response in nature P. 
vivax infection and these PvMSP1P antibodies could be 
maintained for 9  months after recovery from infection. 
Moreover, the P. vivax-infected patients could produce 
antibodies to inhibit PvMSP1P-19 binding to human 
erythrocytes during their acute infection. Those anti-
bodies could sustain strong inhibition until 9  months 
after recovery from infection. The maintenance of anti-
body responses to PvMSP1P-19 was associated with the 
response of MBCs at 9 months after recovery from infec-
tion. A greater understanding of the association between 
the protective immunity and the longevity of MBCs as 
well as plasma cells will be advantageous for future blood 
stage vaccine development against vivax infection.
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Fig. 4 Alteration of  CD19+ B cells and  CD10−CD19+CD27+ memory B cells in P. vivax subjects. a The gating strategy for identifying the  CD19+B 
cells and  CD19+CD10−  CD27+ memory B cells (MBCs) by using flow cytometry. The B cell subsets in the FACS plots are represented for P. vivax‑
infected patients. The lymphocytes were first gated, and then, 100,000 events using  CD19+ were collected to identify the B cell populations. These 
populations were continuously analysed for the expression of  CD10− and  CD27+, which were classified as MBCs. The percentages of  CD19+ B cells 
(b) and  CD19+  CD10−CD27+ MBCs (c) in individuals during acute phase and at 3 and 9 months recovery after P. vivax infeciton (n = 11) are shown. 
Each symbol represents the B cell frequencies for one individual. The horizontal line reflects the median value
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